4 Insights On Decentralized Trials For Biotechs

The COVID-19 pandemic has hastened the adoption of decentralized clinical trials (DCTs) by biopharma companies, transforming the landscape of clinical research. Although the clinician-patient relationship remains crucial to the success of clinical trials, decentralized components like direct-to-patient shipments and telehealth consultations have become permanent fixtures in the process. These innovations not only enhance patient convenience but also improve engagement and retention rates.

By considering the four key insights highlighted in this article, discover how companies can effectively integrate decentralized strategies into their trial designs, optimizing outcomes and advancing clinical research.